Volunteers willing to be deliberately infected with the coronavirus have been asked to step forward after British researchers won ethical approval to hold the world’s first “human challenge trials” for Covid-19.
The government-funded study will begin in the next few weeks and will initially involve as many as 90 healthy participants, aged between 18 and 30.
They will be exposed to the virus in a biosecure research unit at the Royal Free Hospital in London as part of an attempt to learn more about how the virus is transmitted and the immune system’s response.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
